James B. Caress, M.D.
drugs/therapeutic agents pharm, health services, research/outc, neurosciences/behavior
Academic: 336-716-2309 | Department: 336-716-7668
Rutkove SB, Caress JB, Cartwright MS, Burns TM, Warder J, David WS, Goyal N, Maragakis NJ, Benatar M, Sharma KR, Narayanaswami P, Raynor EM, Watson ML, Shefner JM. Electrical impedance myography correlates with standard measures of ALS severity
. Muscle Nerve. 2014;49(3):441-443.
Meininger V, Pradat PF, Corse A, Al-Sarraj S, Rix Brooks B, Caress JB, Cudkowicz M, Kolb SJ, Lange D, Leigh PN, Meyer T, Milleri S, Morrison KE, Orrell RW, Peters G, Rothstein JD, Shefner J, Lavrov A, Williams N, Overend P, Price J, Bates S, Bullman J,. Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial
. PLoS One. 2014;9(5):e97803.
Zhao Y, Cudkowicz ME, Shefner JM, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, Glass J, Rezania K, Harmatz JS, Schoenfeld D, Greenblatt DJ. Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis
. J Clin Pharmacol. 2014;54(10):1180-1187.
Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, Glass J, Rezania K, Rothstein JD, Greenblatt DJ, Cudkowicz ME. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis
. PLoS One. 2013;8(4):e61177.
Vinsant S, Mansfield C, Jimenez-Moreno R, Moore VDG, Yoshikawa M, Hampton TG, Prevette D, Caress J, Oppenheim RW, Milligan C. Characterization of early pathogenesis in the SOD1G93A mouse model of ALS: part I, background and methods
. Brain Behav. 2013;3(4):335-350.
Vinsant S, Mansfield C, Jimenez-Moreno R, Moore VDG, Yoshikawa M, Hampton TG, Prevette D, Caress J, Oppenheim RW, Milligan C. Characterization of early pathogenesis in the SOD1G93A mouse model of ALS: part II, results and discussion
. Brain Behav. 2013;3(4):431-457.
Rutkove S, Caress J, Cartwright M, Burns T, Warder J, David W, Goyal N, Maragakis N, Clawson L, Benatar M, Usher S, Sharma K, Guatam S, Narayanaswarmi P, Raynot E, Watson ML, Shefner J. Electrical impedance myography as a biomarker to assess ALS progression [abstract]. Neurology. 2012;78(Suppl 1):S25.006.
Rutkove SB, Caress JB, Cartwright MS, Burns TM, Warder J, David WS, Goyal N, Maragakis NJ, Clawson L, Benatar M, Usher S, Sharma KR, Gautam S, Narayanaswami P, Raynor EM, Watson ML, Shefner JM. Electrical impedance myography as a biomarker to assess ALS progression
. Amyotroph Lateral Scler. 2012;13(5):439-445.
Hernandez S, Texido L, Caldero J, Ciutat D, Piedrafita L, Casanovas A, Caress J, Prevette D, Oppenheim RW, Milligan C, et al. Increased intramuscular nerve branching and inhibition of programmed cell death of chick embryo motoneurons by immunoglobulins from patients with motoneuron disease
. J Neuroimmunol. 2010;229(1-2):157-168.
Quaid KA, Swenson MM, Sims SL, Harrison JM, Moskowitz C, Stepanov N, Suter GW, Caress J, Walker F, Hunt V, et al. What were you thinking?: individuals at risk for Huntington Disease talk about having children
. J Genet Couns. 2010;19(6):606-617.
Yoshikawa M, Vinsant S, Mansfield CM, Gifondorwa DJ, Pace L, Messi LM [sic] [Messi ML], Caress J, Cartwright M, Delbono O, Oppenheim RW, Milligan CE, et al. Identification of changes in muscle, neuromuscular junctions and spinal cord at early pre-symptomatic stages in the mutant SOD1 mouse model of ALS may provide novel insight for diagnosis and treatment development [abstract]. Soc Neurosci Abstr. 2009;2009(Neuroscience Meeting Planner):.
Shefner JM, Cudkowicz ME, Zhang H, Schoenfeld D, Jillapalli D, Al-Lozi M, Caress JB, David W, Russell J, Graves M, et al. Revised statistical motor unit number estimation in the Celecoxib/ALS trial
. Muscle Nerve. 2007;35(2):228-234.
Caress JB, Esper GJ, Rutkove SB. Neurophysiology of nerve conduction studies In: Blum AS, Rutkove SB, eds. The clinical neurophysiology primer. Totowa (NJ): Humana Press;2007: 207-216.
Caress JB. Technical, physiological and anatomic considerations in nerve conduction studies In: Blum AS, Rutkove SB, eds. The clinical neurophysiology primer. Totowa (NJ): Humana Press;2007: 217-227.
Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Donofrio P, Caress J, Ashburn C, Walker T, Dryman B, et al. Trial of celecoxib in amyotrophic lateral sclerosis
. Ann Neurol. 2006;60(1):22-31.
Shoulson I, Kieburtz K, Oakes D, Kayson E, Zhao H, Shinaman A, Romer M, Caress J, Walker F, Hunt V, et al. At risk for Huntington disease: the PHAROS (Prospective Huntington At Risk Observational Study) Cohort enrolled
. Arch Neurol. 2006;63(7):991-996.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.
The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.
*Dr. Caress is excellent! So happy to have him and the ALS Clinic for my care.
Keep Dr. Caress and make him the head of everything at your hospital and you all will have the highest national standards out there. He could not be a more caring or dedicated neurologist. You all are so lucky to have him!!!! I am thrilled I have gone to Wake rather than Duke even though all I ever hear about is Duke.
Provider exudes confidence!
Very informative provider.
All of my reactions are high, as you see. Dr. Caress is a tribute to his institution.
tho he is very busy, he never cuts short my appointments!
*Doctor Caress is one of the best doctors I have ever had. He is knowledgeable in his field and very compassionate.
If this scale went to 10, I would give him an 11. Every visit with him make ALS easier to handle.
Dr. Caress was wonderful and even offered to look in the archives for my mother's records as he feels I have genetic ALS. I would have loved for him to have had the time to look at all of my testing before the appointment, but I pushed to get it very soon, so I have no doubt he will before my next visit. He took a great deal of time and was very kind and helpful. I had already set up my brother to go him who has a similar disease. Very thankful I was able to find such a kind doctor who is so involved in my disease.
The very best doctor.
After not seeing dr. for 1 yr., spent less than 10 min. with me. Did not review medications or status of research.
Could not ask for a better visit.